Effect of plasma TNF-alpha on filgrastim-stimulated hematopoiesis in mice and humans.
To delineate possible explanations for a nonmonotone hematopoiesis, dose-response curve with filgrastim therapy after high-dose chemotherapy Sequential two-phase study. University teaching hospital and basic pharmaceutical sciences laboratory. Thirty-nine patients with breast cancer or melanoma and 15 normal CF-1 male mice. Serial blood samples were obtained from patients after high-dose chemotherapy to evaluate hematopoiesis and tumor necrosis factor-alpha (TNF-alpha) concentrations. Murine hematopoiesis was induced by filgrastim with or without coadministration of lipopolysaccharide. Detection of plasma TNF-alpha in patients corresponded to substantially slower recovery of granulocytes, erythrocytes, and platelets, and was directly proportional to the prescribed dosage of filgrastim. Lipopolysaccharide stimulated the secretion of TNF-alpha in mice and totally aberrated filgrastim-induced granulopoiesis. This in vivo evidence suggests that regulatory pathways involving endogenous cytokines may override the effect of recombinant cytokines.